Cleverly, Ann L., Eli Lilly and Company, Erl Wood, United Kingdom
-
Vol. 5, No. 11, Nov 2014 - Case Reports
Case Series of Cancer Patients Treated With Galunisertib, a Transforming Growth Factor-Beta Receptor I Kinase Inhibitor in a First-in-Human Dose Study
Abstract HTML PDF